Chemistry:Asandeutertinib

From HandWiki

Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties.[1][2] Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.[1][3]

References

  1. ↑ 1.0 1.1 "Asandeutertinib". PatSnap. https://synapse.patsnap.com/drug/7c59ac82af8f4fb7b9825b2a7f8f2933. 
  2. ↑ "Asandeutertinib". IUPHAR/BPS Guide to PHARMACOLOGY. https://www.guidetomalariapharmacology.org/GRAC/LigandDisplayForward?ligandId=13201. 
  3. ↑ "P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation.". Journal of Thoracic Oncology 19 (10): S195. October 2024. doi:10.1016/j.jtho.2024.09.353. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Asandeutertinib&oldid=4030771"